Spero Therapeutics Announces 3Q17 Operating Results and Pipeline Update
14 déc. 2017 16h15 HE
|
Spero Therapeutics, Inc.
Raised approximately $83.6 million in gross proceeds from Initial Public OfferingAdvanced pipeline with initiation of SPR994 Phase 1 trial in October 2017 and SPR741 Phase 1b trial in November 2017 ...
Spero Therapeutics Announces Underwriters’ Option Exercise
13 nov. 2017 07h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Closing of Initial Public Offering
06 nov. 2017 16h01 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...
Spero Therapeutics Announces Pricing of Initial Public Offering
01 nov. 2017 18h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...
Spero Therapeutics Launches Initial Public Offering
23 oct. 2017 07h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...
Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994
20 oct. 2017 08h00 HE
|
Spero Therapeutics, Inc.
Clinical study to evaluate potential first ever orally administered carbapenem being developed for multi-drug resistant (MDR) Gram-negative infectionsInitiation of pivotal Phase 3 clinical trial in...
Spero Therapeutics Licenses Exclusive Rights to SPR994, a Novel Oral Carbapenem Being Studied for Use in Adults
10 oct. 2017 08h00 HE
|
Spero Therapeutics
-Spero and Meiji Seika Pharma Co., LTD. announce an exclusive license partnership for SPR994 -FDA grants SPR994 Qualified Infectious Disease Product (QIDP) status for complicated urinary tract...
Spero Therapeutics Files Registration Statement for Proposed Initial Public Offering
06 oct. 2017 16h26 HE
|
Spero Therapeutics
CAMBRIDGE, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (“Spero”), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...
Spero Therapeutics Announces Positive Phase 1 Clinical Data From Potentiator Platform
03 oct. 2017 08h00 HE
|
Spero Therapeutics
CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...
Spero Announces Appointment of Frank Thomas to its Board of Directors and Promotions within Leadership Team
06 sept. 2017 08h00 HE
|
Spero Therapeutics
Cristina Larkin promoted to Chief Operating Officer Timothy Keutzer Promoted to Senior Vice President, Development CAMBRIDGE, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a...